Journal article
54 | FIXED DURATION TREATMENT OF BENDAMUSTINE‐RITUXIMAB AND ACALABRUTINIB IN FRONTLINE WALDENSTROM’S MACROGLOBULINEMIA: DEEP MOLECULAR RESPONSES IN HIGH‐RISK PATIENT SUBSETS
Authors
Suleman A; Roos K; Mangoff K; Jiang Y; Klein G; Villa D; MacDonald D; Aljama M; Shafey M; Forward N
Journal
Hematological Oncology, Vol. 43, No. S3,
Publisher
Wiley
Publication Date
June 1, 2025
DOI
10.1002/hon.70093_54
ISSN
0278-0232